AtriCure to Participate in the 2023 Bank of America Health Care Conference and Host a Cryo Nerve Block Therapy Investor Education Webcast
April 19 2023 - 8:00AM
Business Wire
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical
treatments and therapies for atrial fibrillation (Afib), left
atrial appendage (LAA) management and post-operative pain
management, today announced that the company will be hosting an
investor education webcast in conjunction with Canaccord Genuity,
focusing on Cryo Nerve Block Therapy. The company also announced
that it will be participating in the upcoming 2023 Bank of America
Health Care Conference.
AtriCure’s management will be participating in the 2023 Bank of
America Health Care Conference. Management is scheduled to present
on May 10, 2023 at 11:00 a.m. Eastern Time.
AtriCure and Canaccord Genuity will be hosting the Cryo Nerve
Block Therapy Investor Education Webcast at 12:30 pm Eastern Time
on Tuesday, May 16, 2023. The webcast will include a moderated
question and answer session with management and a key opinion
leader.
Interested parties may access a live and archived webcast of
each presentation by visiting the “Investors” section of the
company’s website at https://ir.atricure.com.
About AtriCure
AtriCure, Inc. provides innovative technologies for the
treatment of Afib and related conditions. Afib affects more than 37
million people worldwide. Electrophysiologists and cardiothoracic
surgeons around the globe use AtriCure technologies for the
treatment of Afib and reduction of Afib related complications.
AtriCure’s Isolator® Synergy™ Ablation System is the first medical
device to receive FDA approval for the treatment of persistent
Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System
products are the most widely sold LAA management devices worldwide.
AtriCure’s Hybrid AF™ Therapy is a minimally invasive procedure
that provides a lasting solution for long-standing persistent Afib
patients. AtriCure’s cryoICE cryoSPHERE® probe is cleared for
temporary ablation of peripheral nerves to block pain, providing
pain relief in cardiac and thoracic procedures. For more
information, visit AtriCure.com or follow us on Twitter
@AtriCure.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230419005096/en/
Angie Wirick AtriCure, Inc. Chief Financial Officer (513)
755-5334 awirick@atricure.com
Lynn Lewis or Marissa Bych Gilmartin Group Investor Relations
lynn@gilmartinir.com marissa@gilmartinir.com
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Nov 2024 to Dec 2024
AtriCure (NASDAQ:ATRC)
Historical Stock Chart
From Dec 2023 to Dec 2024
